Whitepapers

Patient recruitment, retention, diversity, & safety are all factors driving the need for radical innovation in clinical research. This need was made painfully apparent during the current COVID-19 pandemic. We can no longer ‘do the same thing and expect a different result’; it’s time to take giant steps forward. Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now.

Over 70% of potential research participants live >2 hours away from a research site, & patient drop-out rates can reach 30% depending on the therapeutic area. The Solution: Medable eConsent Why? 1. Medable eConsent enables the enrollment of underrepresented, diverse populations through remote consenting. 2. Medable eConsent has proven to reduce screening timelines by 50%, & increase patient engagement by 15%+.

A recent study by Morning Consult finds that >54% of US adults would be willing to participate in a clinical trial if it had a 30-minute-or-less commute. This is quite striking, given that <4% of the 328 million people in America are actively participating in clinical research today. The solution? - An accessible, intuitive digital clinical platform that connects sponsors, sites & patients, and replaces burdensome paper forms and physical visits with electronic consents (eConsent), electronic Clinical Outcome Assessments (eCOA’s), and remote visits (TeleVisits). Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now to learn how.

The inVia™ Qontor® microscope's optical tweezing performance depends on the optical properties of the particles and the medium. Typically, it can trap particles smaller than 10 ?m.

View a short podcast with Eurofins BioPharma Product Testing to learn how Eurofins overcomes the challenges faced in sterile fill finish manufacturing in the bio/pharmaceutical industry and solutions for producing small batches of sterile GMP or GLP products for use in Toxicology Studies, as well as Phase I or Phase II clinical trials by eliminating human error and other associated risks.

This paper explores raw material, formulation, process, and equipment design factors that potentially contribute to unexpected early API release from Wurster coated enteric particles.

CPI, a CDMO specializing in Wurster fluid bed coating, has designed and optimized equipment based on linear scaling principles, creating ease and predictability to scale-up.

Antibodies and proteins are critical reagents with wide application in in vitro diagnostic developments, companion diagnostic and biomarker assays. Depending on final application, different quality standards may apply, from research use to full GMP production. Learn more about Curia’s GMP Production of antibodies & proteins for critical assays and diagnostic applications.

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate from formulation development to clinical phase production and commercial manufacturing can be daunting. Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill-finish is successful. Learn more!

Protein engineering has greatly benefited by the advent of in vitro display platforms, where individual or large libraries of peptides or proteins are displayed on the surface of mammalian, yeast, or bacterial cells or even bacteriophage capsids. Learn more about the main principles of phage and yeast surface display platforms & how Curia can power your antibody discovery and engineering projects.

This white paper will highlight critical cleaning standards trending in controlled environments and profile the top cleaning products for COVID-19 and beyond.

The inVia™ Qontor® microscope's optical tweezing performance depends on the optical properties of the particles and the medium. Typically, it can trap particles smaller than 10 ?m.

This paper explores a Quality by Design (QbD) approach to applying Artificial Intelligence (AI) in pharma manufacturing, and demonstrates how to leverage third party platforms to qualify AI algorithms for pharmaceutical product and medical device productivity chains.

CPV will soon become a necessity in pharmaceutical manufacturing, if companies wish to retain a competitive advantage. This paper explores how to embed it into existing production processes to optimize the increasingly pervasive continuous manufacturing ecosystem of today

This application note demonstrates a streamlined HPLC method scouting workflow for the analysis of esomeprazole and related degradation products.